Endometrial Cancer
Background: Endometrial cancer is the most common gynecological cancer affecting women in high-income countries [1,2]. By 2040, endometrial cancer incidence is estimated to increase by more than 50% worldwide compared to 2018 [1]. In the United States in 2023, approximately 66,200 new cases of endometrial cancer will be diagnosed and an estimated 13,030 women will die [2].
Racial health disparities in incidence and mortality of endometrial cancer are pronounced [3,4]. For example, Black women with endometrial cancer have an overall 55% higher five-year mortality risk relative to White women [3]. In Arizona, Hispanic and Native American women have higher incidence and lower survival rates of endometrial cancer compared to non-Hispanic White women [4].
Racial health disparities in incidence and mortality of endometrial cancer are pronounced [3,4]. For example, Black women with endometrial cancer have an overall 55% higher five-year mortality risk relative to White women [3]. In Arizona, Hispanic and Native American women have higher incidence and lower survival rates of endometrial cancer compared to non-Hispanic White women [4].
Projects
Related Projects: Current diagnosis of endometrial cancer requires painful biopsies and the Herbst-Kralovetz Lab is developing painless, non-invasive methods for diagnosis. A study in the lab has focused on protein biomarkers from cervicovaginal lavages as potentially non-invasive diagnostic tools for endometrial cancer. In addition, we are investigating the role of the microbiome, estrobolome, and endometrial cancer. Ongoing studies on endometrial cancer integrate additional multi-omics approaches and quality-of-life analyses.
|
The current and future advancements of endometrial cancer (Adapted from Njoku, Barr, and Crosbie, 2022 using Biorender https://doi.org/10.3389/fonc.2022.890908
|
Published Studies:
- Laniewski P, Cui H, Mahnert ND, Mourad J, Borst MP, Willmott L, Chase DM, Roe DJ, Herbst-Kralovetz MM. Protein biomarkers in cervicovaginal lavages for detection of endometrial cancer. Biomark Res. 2022 Dec 2;10(1):88. doi: 10.1186/s40364-022-00438-5. PMID: 36461062
- Laniewski P, Ilhan ZE, Herbst-Kralovetz MM. The microbiome and gynaecological cancer development, prevention and therapy. Nat Rev Urol. 2020. PMID: 32071434
- Baker JM, Chase DM, Herbst-Kralovetz MM. Uterine Microbiota: Residents, Tourists, or Invaders? Front Immunol. 2018. PMID: 29552006
- Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017. PMID: 28778332
Sources
[1] Zhang S, Gong TT, Liu FH, et al. Global, Regional, and National Burden of Endometrial Cancer, 1990-2017: Results From the Global Burden of Disease Study, 2017. Front Oncol. 2019;9:1440. Published 2019 Dec 19. doi:10.3389/fonc.2019.01440
[2] American Cancer Society. Endometrial Cancer Statistics. Published January 12, 2023. https://www.cancer.org/cancer/types/
endometrial-cancer/about/key-statistics.html
[3] Doll KM, Snyder CR, Ford CL. Endometrial cancer disparities: a race-conscious critique of the literature. Am J Obstet Gynecol. 2018;218(5):474-482.e2. doi:10.1016/j.ajog.2017.09.016
[4] Batai K, Gachupin FC, Estrada AL, Garcia DO, Gomez J, Kittles RA. Patterns of Cancer Related Health Disparities in Arizona. Cancer Health Disparities. 2019;3:e1-e20.
[2] American Cancer Society. Endometrial Cancer Statistics. Published January 12, 2023. https://www.cancer.org/cancer/types/
endometrial-cancer/about/key-statistics.html
[3] Doll KM, Snyder CR, Ford CL. Endometrial cancer disparities: a race-conscious critique of the literature. Am J Obstet Gynecol. 2018;218(5):474-482.e2. doi:10.1016/j.ajog.2017.09.016
[4] Batai K, Gachupin FC, Estrada AL, Garcia DO, Gomez J, Kittles RA. Patterns of Cancer Related Health Disparities in Arizona. Cancer Health Disparities. 2019;3:e1-e20.